ScholarLens Back to search
2001•肿瘤研究与临床Requires access

EXPRESSION AND CLINICAL VALUE OF CD44v6 AND nm23 IN HUMAN CARCINOMA OF LUNG

魏金芝, Song He, 朱亚芳

Open publisher page 0 citations

Abstract

目的:探讨CD44v6和nm23在肺癌组织中的表达及意义.方法:应用免疫组织化学方法,检测51例肺癌组织中CD44v6和nm23的表达情况,并分析其临床意义.结果:在5例类癌和4例小细胞肺癌(SCLC)中未见CD44v6表达.在非小细胞肺癌(NSCLC)中,≤60岁和＞60岁组CD44v6的阳性率分别为84.0%和29.4%,两组间差异有非常显著性(X2=12.79;P＜0.01),低分化癌和高中分化癌中CD44v6的阳性率分别为87.0%和31.6%,两组间差异有显著性(X2=13.53,P＜0.01);有和无淋巴结转移组CD44v6的阳性率分别为73.3%和33.3%,两组间差异有显著性(X2=5.82,P＜0.05);鳞癌和腺癌中CD44v6的阳性率分别为85.7%和50.0%,两组间差异有显著性(X2=5.05,P＜0.05);nm23在腺癌和鳞癌中的阳性率分别为64.3%和14.3%,两组间差异有显著性(X2=9.35,P＜0.01).结论:CD4tv6可反映NSCLC的生物学特性,是预测其侵袭转移潜能和预后的指标.nm23能否作为肺癌的预后指标尚待扩大样本深入研究.

About this research paper

What this paper is about

目的:探讨CD44v6和nm23在肺癌组织中的表达及意义.方法:应用免疫组织化学方法,检测51例肺癌组织中CD44v6和nm23的表达情况,并分析其临床意义.结果:在5例类癌和4例小细胞肺癌(SCLC)中未见CD44v6表达.在非小细胞肺癌(NSCLC)中,≤60岁和＞60岁组CD44v6的阳性率分别为84.0%和29.4%,两组间差异有非常显著性(X2=12.79;P＜0.01),低分化癌和高中分化癌中CD44v6的阳性率分别为87.0%和31.6%,两组间差异有显著性(X2=13.53,P＜0.01);有和无淋巴结转移组CD44v6的阳性率分别为73.3%和33.3%,两组间差异有显著性(X2=5.82,P＜0.05);鳞癌和腺癌中CD44v6的阳性率分别为85.7%和50.0%,两组间差异有显著性(X2=5.05,P＜0.05);nm23在腺癌和鳞癌中的阳性率分别为64.3%和14.3%,两组间差异有显著性(X2=9.35,P＜0.01).结论:CD4tv6可反映NSCLC的生物学特性,是预测其侵袭转移潜能和预后的指标.nm23能否作为肺癌的预后指标尚待扩大样本深入研究.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

目的:探讨CD44v6和nm23在肺癌组织中的表达及意义.方法:应用免疫组织化学方法,检测51例肺癌组织中CD44v6和nm23的表达情况,并分析其临床意义.结果:在5例类癌和4例小细胞肺癌(SCLC)中未见CD44v6表达.在非小细胞肺癌(NSCLC)中,≤60岁和＞60岁组CD44v6的阳性率分别为84.0%和29.4%,两组间差异有非常显著性(X2=12.79;P＜0.01),低分化癌和高中分化癌中CD44v6的阳性率分别为87.0%和31.6%,两组间差异有显著性(X2=13.53,P＜0.01);有和无淋巴结转移组CD44v6的阳性率分别为73.3%和33.3%,两组间差异有显著性(X2=5.82,P＜0.05);鳞癌和腺癌中CD44v6的阳性率分别为85.7%和50.0%,两组间差异有显著性(X2=5.05,P＜0.05);nm23在腺癌和鳞癌中的阳性率分别为64.3%和14.3%,两组间差异有显著性(X2=9.35,P＜0.01).结论:CD4tv6可反映NSCLC的生物学特性,是预测其侵袭转移潜能和预后的指标.nm23能否作为肺癌的预后指标尚待扩大样本深入研究.

Key concepts: Value (mathematics), Human lung, Carcinoma, Expression (computer science), Lung, Medicine, Internal medicine, Computer science

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
EXPRESSION AND CLINICAL VALUE OF CD44v6 AND nm23 IN HUMAN CARCINOMA OF LUNG — Research Paper | ScholarLens